Alvogen cleared to market Qsymia in South Korea

22 August 2019

Privately-owned US drugmaker Alvogen has obtained marketing approval for Qsymia (phentermine and topiramate extended-release) from the South Korea Ministry of Food and Drug Safety (MFDS) in partnership with Vivus Inc (Nasdaq: VVUS).

Under an agreement between the parties from 2017, Alvogen is responsible for obtaining and maintaining regulatory approvals and sales and marketing activities in Korea.

Petar Vazharov executive vice president, sales and marketing of Alvogen APAC region, says: “Alvogen Korea has traditionally a strong position in anti-obesity therapies and brand awareness. The approval of Qsymia is an important upgrade to the existing portfolio and is our response to the increasing competition from a newer generation of anti-obesity products in the Korean market. The product was approved by US FDA in 2012 for long term weight management. As we are celebrating the approval, our team in Korea is actively preparing for the product launch.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK